Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$68.34 -1.5%	$64.75	$47.86 ▼ $107.37	$3.77B	0.28	605,895 shs	531,382 shs
NRIX Nurix Therapeutics	$11.27 +0.1%	$11.47	$8.18 ▼ $29.56	$861.21M	2.15	847,374 shs	421,123 shs
RNA Avidity Biosciences	$33.47 -1.6%	$30.98	$21.51 ▼ $56.00	$4.03B	0.91	1.42 million shs	863,360 shs
SWTX SpringWorks Therapeutics	$46.99	$46.74	$28.21 ▼ $62.00	$3.54B	0.68	2.64 million shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+2.66%	-0.76%	+10.14%	+9.93%	+10.92%
NRIX Nurix Therapeutics	+0.36%	-11.35%	-2.09%	-1.83%	-45.86%
RNA Avidity Biosciences	+0.77%	+1.34%	+16.07%	+15.52%	-24.60%
SWTX SpringWorks Therapeutics	0.00%	0.00%	+0.06%	+16.02%	+24.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.5456 of 5 stars	3.5	2.0	2.9	2.5	0.0
NRIX Nurix Therapeutics	2.7647 of 5 stars	4.4	1.0	3.7	0.8	0.0
RNA Avidity Biosciences	2.5234 of 5 stars	4.5	0.0	3.5	0.8	0.0
SWTX SpringWorks Therapeutics	1.5214 of 5 stars	3.1	2.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	62.75% Upside
NRIX Nurix Therapeutics	2.82	Moderate Buy	$29.31	160.21% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	98.25% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside

Current Analyst Ratings Breakdown

Latest NRIX, RNA, ACLX, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	34.89	N/A	N/A	$8.41 per share	8.13
NRIX Nurix Therapeutics	$54.55M	15.79	N/A	N/A	$7.44 per share	1.51
RNA Avidity Biosciences	$10.90M	370.07	N/A	N/A	$11.94 per share	2.80
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest NRIX, RNA, ACLX, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
8/6/2025	Q2 2025	SWTX SpringWorks Therapeutics	-$0.81	N/A	N/A	N/A	$73.39 million	N/A
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
NRIX Nurix Therapeutics	N/A	6.82	6.82
RNA Avidity Biosciences	N/A	16.91	16.91
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
NRIX Nurix Therapeutics	N/A
RNA Avidity Biosciences	N/A
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
NRIX Nurix Therapeutics	7.40%
RNA Avidity Biosciences	3.83%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

NRIX, RNA, ACLX, and SWTX Headlines

Recent News About These Companies

European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients

July 18, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

July 18, 2025 | quiverquant.comQ

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

SpringWorks Therapeutics (NASDAQ:SWTX) Receives $52.57 Consensus Price Target from Brokerages

July 17, 2025 | americanbankingnews.com

SpringWorks Therapeutics (NASDAQ:SWTX) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

July 17, 2025 | americanbankingnews.com

Principal Financial Group Inc. Trims Stake in SpringWorks Therapeutics (NASDAQ:SWTX)

July 7, 2025 | marketbeat.com

37,543 Shares in SpringWorks Therapeutics (NASDAQ:SWTX) Bought by CIBRA Capital Ltd

July 2, 2025 | marketbeat.com

SpringWorks Therapeutics Completes Merger and Delisting

July 1, 2025 | tipranks.com

SpringWorks Therapeutics Inc (SWTX) - Investing.com

June 28, 2025 | investing.com

AMI Asset Management Corp Purchases 10,849 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 26, 2025 | marketbeat.com

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 26, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership

NRIX, RNA, ACLX, and SWTX Company Descriptions

Arcellx NASDAQ:ACLX

$68.34 -1.05 (-1.51%)

Closing price 03:58 PM Eastern

Extended Trading

$68.22 -0.12 (-0.18%)

As of 04:04 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Nurix Therapeutics NASDAQ:NRIX

$11.26 +0.02 (+0.13%)

Closing price 03:58 PM Eastern

Extended Trading

$11.26 -0.01 (-0.09%)

As of 04:04 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Avidity Biosciences NASDAQ:RNA

$33.47 -0.55 (-1.62%)

Closing price 03:58 PM Eastern

Extended Trading

$33.49 +0.02 (+0.06%)

As of 04:04 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)

As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time